Overview

A Study to Assess the Safety and Efficacy of Levodopa-carbidopa Intestinal Gel (LCIG) for the Treatment of Non-motor Symptoms in Patients With Advanced Parkinson's Disease

Status:
Completed

Trial end date:
2015-12-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to evaluate change in non-motor symptoms from baseline to Week 12 as measured by the Non-Motor Symptom Scale total score.

Phase:

Phase 3

Details

Lead Sponsor:

AbbVie (prior sponsor, Abbott)

Treatments:

Carbidopa
Carbidopa, levodopa drug combination
Levodopa